Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

AGEN - Agenus Inc. So'nggi Yangiliklar | Finranks

Home

/

AGEN

A

Agenus Inc. (AGEN)

NCM – Real vaqt narxi. Valyuta: USD

7.13

+0.29 (4.32%)

Bozor ochiq: Aug 12, 2026, 3:26 PM EDT

6.86

+0.03 (0.44%)

Oldingi bozordan keyin: Aug 11, 2026, 7:47 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates

Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates

Agenus (AGEN) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.05. This compares to a loss of $1 per share a year ago.

Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer

Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the second quarter ended June 30, 2026, and provided an update on its financing-supported strategy to advance botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, plus balstilimab (BAL), an anti-PD-1 antibody, in a curative-intent treatment setting before surgery in high-risk, resectable microsatellite-stable (MSS) colon cancer. As previ.

Videolar

No Data

There is no data to display

Press-relizlar

Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer

Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the second quarter ended June 30, 2026, and provided an update on its financing-supported strategy to advance botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, plus balstilimab (BAL), an anti-PD-1 antibody, in a curative-intent treatment setting before surgery in high-risk, resectable microsatellite-stable (MSS) colon cancer. As previ.